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www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: Average patient age was 81.26.1 years with most patients being in NYHA
III/IV (95.7%). The transfemoral route was the most common access site (78.3%) with
an equal number of patients receiving the Edwards and CoreValve bioprostheses. The
largest expense was the TAVI procedure and the subsequent in-hospital stay,
excluding intensive care unit stay, ($52,052). The average “pathway” cost per patient
up to the point of discharge was $860879613. This included clinic appointments at
the specialized TAVI clinic, investigations, the procedure itself as well as the sub-
sequent hospital stay. Comparison between the 2 valves suggested that the cost was
slightly higher for CoreValve as compared to Edwards ($8905811663 vs.
$831177564, p¼0.05) although this was due to the higher cost of the CoreValve and
the more frequent need for permanent pacemaker associated with this. No signiﬁcant
differences were noted between the 2 valves when these 2 factors were excluded
($6320811324 vs. 596927564, p¼0.26).
Conclusions: Although expensive, TAVI is justiﬁed by the improvements in long-
term mortality in inoperable patients as compared to medical therapy alone. Increasing
competition, improvements in valve technology and other procedural parameters are
likely to make TAVI cheaper. Future trials should prospectively assess the “pathway”
costs for both TAVI and conventional surgery, rather than just procedural costs.
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Background: The purpose of this study was to demonstrate the feasibility and pro-
cedural outcomes with the Colibri Transcatheter Aortic Heart Valve. The Colibri Heart
valve is the lowest proﬁle (14Fr) ﬁrst dry valve. It comes completely crimped and
sterilized ready for use from the package to the patient. Currently available heart
valves, for surgical or catheter implantation, require rinsing of the chemicals they
contain and crimping of the valve (TAVI cases) before implantation. We describe here
the outcome of the ﬁrst in human cohort of implants of the Colibri Heart Valve up to
15 months of follow up.
Methods: After the initial successful clinical and hemodynamics results of the ﬁrst
Colibri Transcatheter Aortic Valve Implant (CTAVI), we performed, under a
compassionate use protocol, four additional consecutive CTAVI patients with severe
aortic stenosis who were not surgical candidates. All patients were symptomatic,
NYHA class 3-4, and had preserved ejection fraction. The ﬁve patients’ average aortic
valve mean gradient (MG) pre-procedure was 53 mmHg and the average aortic valve
area (AVA) of 0.71 cm2. All cases were accessed transfemoral after surgical exposure
of the artery. Balloon aortic valvuloplasty was performed before the CTAVI
implantation.
Results: The valve was implanted successful in the orthotopic position in all cases
using rapid ventricular pacing and ﬂuoroscopic guidance. The MG decreased to 8.4
mmHg and the AVA increased to 2.2 cm2, there were no transvalvular regurgitations,
no need for permanent pacemaker and no stroke. One case had mild paravalvular
insufﬁciency. All patients were discharged home ambulatory . Follow-up for 15
months (n1), 7 months (n1) and 3 months (n3) with excellent clinical outcomes
NYHA 1, no evidence of major adverse events and maintenance of mean gradients of
10 mmHg and AVA of 2.2 cm2.
Conclusions: The Colibri HV implantations, the world’s ﬁrst pre-package, sterilized,
dry valve and ready for use 14Fr system is feasible and safe. The beneﬁcial clinical
and hemodynamic outcomes are persistent up to 15 months with low gradients and
large aortic valve area. This low proﬁle valve opens the opportunity to treat patients
with small femoral arteries.
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Background: Direct ﬂow medical (DFM) prosthesis is a non-metallic, repositionable
and retrievable bioprosthetic valve which has never been previously compared with
current status of care. In this study we sought to compare the procedural and 30-day
outcome after transcatheter aortic valve implantation (TAVI) with three different
prostheses: DFM vs. Medtronic CoreValve (MCV) vs. Edwards Sapien XT (ES).
Methods: Twenty-one consecutive patients treated with DFM for severe aortic ste-
nosis were matched to an equal sample of patients undergoing TAVI with MCV and
ES (1:1:1 propensity score-matching). Primary end-point was 30-day safety, deﬁnedJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Vaaccording to the VARC criteria as the composite of all-cause mortality, stroke, life-
threatening bleeding, stage-2 or -3 acute kidney injury, coronary artery obstruction
requiring intervention, major vascular complications or repeat procedures for valve-
related dysfunction. Secondary end-points were: post-TAVI transaortic gradient
reduction; and device success.
Results: Baseline comparison between patients treated with different prostheses
revealed no signiﬁcant demographic and clinical characteristics. Patients treated with
DFM had higher safety rates, with respect to MCV and ES (respectively 90.5% vs.
42.9% vs. 57.1%; p¼0.004) at 30-day follow up. Post-TAVI transaortic gradient
reduction was similar for DFM, MCV and ES subgroups (8.35.2 mmHg vs. 5.33.7
mmHg vs. 5.65.1mmHg, respectively; p¼0.155). Likewise, devise success did not
differ signiﬁcantly (100% vs. 95.2% vs. 90.5%, respectively, p ¼0.21). In the pooled
binary logistic regression analysis, DFM prosthesis was independent predictor of early
safety (DFM vs. MCV: OR 11.2, 95% CI 1.9-66.7, p¼0.008; and DFM vs. ES: OR
5.8, 95% CI 1.0-35.7, p¼0.056).
Conclusions: DFM prosthesis has a better safety proﬁle when compared to MCV and
ES. Device success and short-term outcome rates were comparable between patients
treated with DFM, MCV or ES.
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Background: Renin angiotensin system (RAS) blockade with angiotensin-converting
enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) have survival
beneﬁt in heart failure. Persistent heart failure after surgical aortic valve replacement
(SAVR) for severe aortic stenosis (AS) is associated with poor outcome. Data are
lacking on the impact of RAS blockade after SAVR for severe AS.We sought to
investigate the impact ofassociation between RAS blockade therapy on and outcomes
following SAVR for severe AS.
Methods: Patients prescribed ACEI/ARB after SAVR for severe AS between 1991
and 2010, with at least 2 reﬁlls 90 days apart and at least 6 month follow up in our
health system constituted the RAS blockade group (n¼741) and those not prescribed
ACEI/ARB were the untreatedcontrol group (n¼1,011). Unadjusted and propensity
matched analyses (treatedcase: control untreated ratio of 1:1 yielding 594 matched
pairs) were performed. Primary outcome was survival after SAVR. Secondary end
points were changes in left ventricular mass index (LVMI), left ventricular ejection
fraction (LVEF) and left atrial (LA) size after SAVR.
Results: A total of 562 deaths occurred over a mean follow up of 6.3  4.1 years.
Overall unadjusted estimated survival at 1, 5 and 10 years was 99%, 90% and 69% in
the RAS group compared to 99%, 81% and 53% respectively in the non-RAS group
(p< 0.0001). Among propensity matched patients, estimated survival at 1, 5 and 10
years remained signiﬁcantly higher in the RAS group compared to non-RAS group
(99%, 90% and 71% vs. 96%, 78% and 49%, respectively p< 0.0001). When stratiﬁed
by concomitant CABG, survival remained signiﬁcantly higher in the RAS group
(unadjusted and propensity matched, p< 0.0001). For the matched cohorts, on
echocardiographic analysis there were no signiﬁcant group differences between the
RAS and non RAS groups with respect to change in LVMI (p¼0.37),LVEF(p¼0.67)
and LA size (p¼0.43) after SAVR
Conclusions: RAS blockade is associated with an improved survival in patients
following AVR for severe AS. Therapy with ACEI/ARB should be considered in
patients after AVR for AS if proven beneﬁcial in a randomized controlled trial.
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Background: CT analyses of patients with aortic stenosis reveal that in many patients
the aortic annulus is eccentric. Therefore, the aim of this study was to assess the
performance of the transapical Jenavalve in an in vitro hydrodynamic and durability
test model comparing circular and eccentric aortic annulus geometry.
Methods: Based on CT-data from 123 consecutive TAVI-patients, a mean annulus
eccentricity (eccentricity¼short diameter/long diameter) of 0.84 was determined.
Two models of aortic roots with valve leaﬂets, one circular in shape and one dis-
playing an eccentricity of 0.84 were created with oriﬁce areas corresponding to a
circular 27mm annulus. Valve hydrodynamics were evaluated at different ﬂow rateslvular disease - Aortic: TAVR B219
